[
    [
        {
            "time": "",
            "original_text": "天坛生物(600161.SH)：“注射用重组人凝血因子Ⅷ”取得临床试验总结报告",
            "features": {
                "keywords": [
                    "天坛生物",
                    "注射用重组人凝血因子Ⅷ",
                    "临床试验",
                    "总结报告"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "天坛生物(600161.SH)：“注射用重组人凝血因子Ⅷ”取得临床试验总结报告",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "天坛生物：“注射用重组人凝血因子Ⅷ”和“静注人免疫球蛋白(pH4、10%) (层析法)”完成了Ⅲ期临床试验",
            "features": {
                "keywords": [
                    "天坛生物",
                    "注射用重组人凝血因子Ⅷ",
                    "静注人免疫球蛋白",
                    "Ⅲ期临床试验"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "天坛生物：“注射用重组人凝血因子Ⅷ”和“静注人免疫球蛋白(pH4、10%) (层析法)”完成了Ⅲ期临床试验",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "天坛生物(600161.SH)：成都蓉生研制的“静注人免疫球蛋白(pH4、10%) (层析法)”完成了Ⅲ期临床试验并取得临床试验总结报告",
            "features": {
                "keywords": [
                    "天坛生物",
                    "成都蓉生",
                    "静注人免疫球蛋白",
                    "Ⅲ期临床试验",
                    "总结报告"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "天坛生物(600161.SH)：成都蓉生研制的“静注人免疫球蛋白(pH4、10%) (层析法)”完成了Ⅲ期临床试验并取得临床试验总结报告",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "天坛生物(600161.SH)：成都蓉生研制的“注射用重组人凝血因子Ⅷ”完成了Ⅲ期临床试验并取得临床试验总结报告",
            "features": {
                "keywords": [
                    "天坛生物",
                    "成都蓉生",
                    "注射用重组人凝血因子Ⅷ",
                    "Ⅲ期临床试验",
                    "总结报告"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "天坛生物(600161.SH)：成都蓉生研制的“注射用重组人凝血因子Ⅷ”完成了Ⅲ期临床试验并取得临床试验总结报告",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "天坛生物(600161.SH)：所属浆站获得单采血浆许可证",
            "features": {
                "keywords": [
                    "天坛生物",
                    "浆站",
                    "单采血浆许可证"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "天坛生物(600161.SH)：所属浆站获得单采血浆许可证",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        }
    ]
]